A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Epilepsies, Myoclonic

In brief

The primary purpose of the study is to demonstrate that lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in participants with Dravet syndrome.

Key facts

Study ID
NCT04572243
Run by
Eisai Inc.
People needed
22
Starts
2020-09-23
Expected to finish
2024-08-15
Last updated by the study team
2025-10-08

Who can join

Age: 2 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.